Fusion protein strategy to increase expression and solubility of hypervariable region of VP2 protein of infectious bursal disease virus in Escherichia coli

scientific article published in October 2012

Fusion protein strategy to increase expression and solubility of hypervariable region of VP2 protein of infectious bursal disease virus in Escherichia coli is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1015640072
P356DOI10.1007/S10930-012-9437-2
P698PubMed publication ID22865249

P2093author name stringMehdi Shamsara
Azar Shahpiri
Sahar Sadat Sedighzadeh
P2860cites workHigh yield, purity and activity of soluble recombinant Bacteroides thetaiotaomicron GST-heparinase I from Escherichia coliQ36012748
Acute infectious bursal disease in poultry: a reviewQ37382392
Biochemistry and immunology of infectious bursal disease virusQ39245775
Effect of Infectious Bursal Agent on the Response of Chickens to Newcastle Disease and Marek's Disease VaccinationQ40012986
Affinity fusion strategies for detection, purification, and immobilization of recombinant proteinsQ41608082
Identification of a novel viral protein in infectious bursal disease virus-infected cellsQ42689283
Infectious bursal disease subunit vaccinationQ44809254
Cloning and nucleotide analysis of the vp2 gene of a very virulent infectious bursal disease virus isolate from Iran.Q45409007
Cloning and expression of the VP2 gene of an infectious bursal disease virus.Q45743523
Molecular basis of antigenic variation in infectious bursal disease virusQ45778525
Pathogenesis of Highly Virulent Infectious Bursal Disease Virus Infection in Intact and Bursectomized ChickensQ45786571
The characterization and molecular cloning of the double-stranded RNA genome of an Australian strain of infectious bursal disease virusQ45837878
Properties of RNA polymerase activity associated with infectious bursal disease virus and characterization of its reaction productsQ45842451
Comparative studies on structural and antigenic properties of two serotypes of infectious bursal disease virusQ45847698
Physicochemical and immunological characterization of recombinant host-protective antigen (VP2) of infectious bursal disease virusQ45857478
A recombinant fowlpox virus that expresses the VP2 antigen of infectious bursal disease virus induces protection against mortality caused by the virus.Q45861659
Critical amino acid changes in VP2 variable domain are associated with typical and atypical antigenicity in very virulent infectious bursal disease virusesQ48022473
Molecular characterization of Iranian infectious bursal disease viruses.Q48071428
Escherichia coli fusion carrier proteins act as solubilizing agents for recombinant uncoupling protein 1 through interactions with GroEL.Q54484269
Maternally derived antibody--effect on susceptibility of chicks to infectious bursal disease.Q54616754
Outbreak of virulent infectious bursal disease in East AngliaQ57112546
New fusion protein systems designed to give soluble expression in Escherichia coliQ73041803
Isolation and characterization of a very virulent Infectious bursal disease virus from turkeyQ84957319
Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferaseQ27860571
Requirement for the carboxyl-terminal domain of Saccharomyces cerevisiae carbamoyl-phosphate synthetaseQ27930794
Analysis and control of proteolysis of recombinant proteins in Escherichia coli.Q35816892
P433issue7
P407language of work or nameEnglishQ1860
P921main subjectEscherichia coliQ25419
Infectious bursal disease virusQ707615
P304page(s)580-584
P577publication date2012-10-01
P1433published inThe Protein JournalQ15760422
P1476titleFusion protein strategy to increase expression and solubility of hypervariable region of VP2 protein of infectious bursal disease virus in Escherichia coli
P478volume31

Reverse relations

cites work (P2860)
Q54318839Modification in media composition to obtain secretory production of STxB-based vaccines using Escherichia coli.
Q41230389gga-miR-9* inhibits IFN production in antiviral innate immunity by targeting interferon regulatory factor 2 to promote IBDV replication

Search more.